Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term single-chain fv. Found 14 abstracts

Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Robinson MK. Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumor Biology. 2012 Jun;33(3):617-27.   PMCID: not NIH funded
Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Stahl S, Carlsson J. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biotherapy and Radiopharmaceuticals. 2005 Jun;20(3):239-48.
Weiner LM, Carter P. Tunable antibodies. Nat Biotechnol. 2005 May;23(5):556-7.
Robinson MK, Weiner LM, Adams GP. Improving monoclonal antibodies for cancer therapy. Drug Development Research. 2004 Mar;61(3):172-87.
Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, Stahl S. Selection and characterization of HER2/neu-binding affibody ligands. Protein Engineering Design & Selection. 2004 May;17(5):455-62.
Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 2000 Nov 15;60(22):6434-40.
Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000 Sep;301(5):1149-61.
Adams GP. Improving the tumor specificity and retention of antibody-based molecules. In Vivo. 1998 Jan;12(1):11-21.
Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer. 1998 May;77(9):1405-12.
Bookman MA. Biological therapy of ovarian cancer: Current directions. Semin Oncol. 1998 Jun;25(3):381-96.
Amoroso AR, Clark JI, Litwin S, HsiehMa S, Shi T, Alpaugh RK, Adams GP, Wolf EJ, Ring DB, Weiner LM. Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor. Cancer Res. 1996 Jan;56(1):113-20.
Adams GP, McCartney JE, Wolf EJ, Oppermann H, Tai MS, Eisenberg J, Giantonio B, Schultz J, Bookman MA, Laminet AA, Apell G, Stafford WF, Liu S, Huston JS, Houston LL, Weiner LM. Preclinical Studies and Optimization of Specific Tumor Delivery for 741f8 Sfv, an Anti-C-Erbb-2 Single-Chain Species. International Journal of Pharmacognosy. 1995 Jan;33:75-91.
McCartney JE, Tai MS, Hudziak RM, Adams GP, Weiner LM, Jin D, Stafford WF, Liu S, Bookman MA, Laminet AA, Fand I, Houston LL, Oppermann H, Huston JS. Engineering Disulfide-Linked Single-Chain Fv Dimers (Sfv')(2) with Improved Solution and Targeting Properties - Antidigoxin- 26-10 (Sfv')(2) and Anti-C-Erbb-2 741f8 (Sfv')(2) Made by Protein-Folding and Bonded through C-Terminal Cysteinyl Peptides. Protein Eng. 1995 Mar;8(3):301-14.
Bookman MA. Biologic Therapy in the Management of Refractory Ovarian-Cancer. Gynecol Oncol. 1993 Oct;51(1):113-26.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term single-chain fv

single-chain fv escherichia-coli monoclonal-antibody b-cell lymphoma tumor targeting protein phase-i trial fragments immunoglobulin forms antibodies biodistribution monoclonal-antibodies nude-mice radiolabeling colony-stimulating factor tumor-necrosis-factor mice recombinant gamma-interferon cancer breast-cancer factor receptor expression expression binding-site affinity bivalent growth-inhibition imaging human monoclonal-antibodies dose diabody c-erbb-2 oncogene monoclonal antibodies bispecific monoclonal- non-hodgkins-lymphoma cytotoxicity c-ErbB-2 affibody-HER-2-iodine-radionuclide-SKBR-3-tumor epidermal growth-factor tumor penetration avidity cells display library tissue binding-properties staphylococcal protein-a in-vitro binding-site barrier bacterial receptor domain HER2 affibody-ligand-phage display-selection single chain her-2 receptor human transferrin monoclonal-antibody co17-1a enzyme fusion evolution early prediction tumors binding-proteins human carcinoma xenografts selection glycosylation antibody fragment single-chain Fv optimized delivery killer-cells phage-display technology signal-transduction idiotype antibodies proteins bispecific antibodies (sfv')(2) colorectal-cancer carcinoma cytotoxic lymphocytes-t vascular leak syndrome chimeric antibodies 1995 oe ys-journal of medicinal chemistry-v38-p816 tumour targeting binding sites tyrosine kinases Fv t- c-erb-2 extracellular domain ovarian-cancer sfv single chain Fv receptor mediated endocytosis cell-binding nonspecific animal toxicity neu oncoprotein pichia-pastoris activated killer-cells taq dna-polymerase combinatorial libraries library carcinoma ascitic fluid model metastatic breast-cancer distribution human lymphocytes-t phage antibody library fc-gamma-riii endothelial growth-factor digoxin immuno-targeting pharmacokinetics monoclonal-antibody hmfg2 hybrid hybridomas delivery (sfv')(2) dimers miniantibodies recovery lymphocytes c-erbb-2 immunodeficient mice phase-i dna her-2 neu nude- positron-emission-tomography HER2 Diabody-Pichia-E coli-PET imaging activated trial ErbB2 surface display internalization phage display fusion protein transformation human-breast-cancer
Last updated on Tuesday, July 08, 2014